These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3134318)

  • 1. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
    Matsushita S; Yamada S; Kudoh Y; Ohashi M
    Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
    Vanhoof R; Hubrechts JM; Roebben E; Nyssen HJ; Nulens E; Leger J; De Schepper N
    Infection; 1986; 14(6):294-8. PubMed ID: 3546145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrophobicity and serum sensitivity of Klebsiella pneumoniae treated with sub-MICs of quinolones.
    Hostacká A
    Microbios; 1997; 91(368-369):137-43. PubMed ID: 9523422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I; Verbist L; Vandepitte J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
    Appleman ME; Hadfield TL; Gaines JK; Winn RE
    Diagn Microbiol Infect Dis; 1987 Oct; 8(2):131-3. PubMed ID: 2892608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.